home / stock / enta / enta news

ENTA News and Press, Enanta Pharmaceuticals Inc. From 05/09/23

Stock Information
Company Name: Enanta Pharmaceuticals Inc.
Stock Symbol: ENTA
Market: NASDAQ
Website: enanta.com
Menu
ENTA ENTA Quote ENTA Short ENTA News ENTA Articles ENTA Message Board
Get ENTA Alerts

News, Short Squeeze, Breakout and More Instantly...
ENTA - ES, SFWL and MOBQ among mid-day movers

2023-05-09 13:22:40 ET Gainers: TScan Therapeutics ( TCRX ) +124% . Shengfeng Development Limited ( SFWL ) +102% . Mobiquity Technologies ( MOBQ ) +68% . ClearOne ( CLRO ) +62% . U.S. GoldMining ( USGOW ) +57% . Novavax ( N...
ENTA - TScan, Ensysce top healthcare gainers; Enanta, Lexaria among losers

2023-05-09 10:00:33 ET Gainers: TScan Therapeutics ( TCRX ) +151% . Ensysce Biosciences ( ENSC ) +60% . Novavax ( NVAX ) +36% . Y-mAbs Therapeutics ( YMAB ) +30% . Longeveron ( LGVN ) +26% . Losers: Enanta Pharmaceuti...

ENTA - Enanta Pharmaceuticals to Participate in Two Investor Conferences in May

Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in May:...

ENTA - Enanta Pharmaceuticals, Inc. (ENTA) Q2 2023 Earnings Call Transcript

2023-05-08 18:48:06 ET Enanta Pharmaceuticals, Inc. (ENTA) Q2 2023 Earnings Conference Call May 08, 2023 04:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President & Chief Executive Officer Scott Rottinghaus - Chief Medical Offi...
ENTA - ANTRA, ENTA and YMAB are among after hour movers

2023-05-08 18:03:40 ET Gainers: Oportun Financial  ( OPRT ) +23% . EverQuote ( EVER ) +22% . Tactile Systems Technology ( TCMD ) +17% . Rover Group ( ROVR ) +14% . Y-mAbs Therapeutics ( YMAB ) +13% . Losers: Enanta P...

ENTA - Enanta falls 21% as fiscal 2023 Q2 revenue misses

2023-05-08 17:48:08 ET Enanta Pharmaceuticals ( NASDAQ: ENTA ) is down 21% in after-hours trading after its fiscal 2023 Q2 results missed on the top line. Revenue of $17.8M was a ~5% year-over-year decline. Consensus was $19.06M. Enanta's ( ENTA ) net loss widene...

ENTA - Enanta Pharma Q2 2023 Earnings Preview

2023-05-08 17:35:58 ET Enanta Pharma ( NASDAQ: ENTA ) is scheduled to announce Q2 earnings results on Tuesday, May 9th, after market close. The consensus EPS Estimate is -$1.93 (-18.4% Y/Y) and the consensus Revenue Estimate is $19.06M (+1.8% Y/Y). Over the last 1 year...
ENTA - Enanta Pharma GAAP EPS of -$1.79 beats by $0.13, revenue of $17.8M misses by $1.26M

2023-05-08 16:07:41 ET Enanta Pharma press release ( NASDAQ: ENTA ): FQ2 GAAP EPS of -$1.79 beats by $0.13 . Revenue of $17.8M (-4.8% Y/Y) misses by $1.26M . For further details see: Enanta Pharma GAAP EPS of -$1.79 beats by $0.13, revenue of $17.8M misse...

ENTA - Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19

Study Met Primary Endpoints of Safety and Tolerability Dose-Dependent Improvement in Total Symptom Score Observed with EDP-235 Treatment Compared to Placebo, Achieving Statistical Significance as Early as One Day After First Dose No Difference in Viral Load Reduction; Rapid Declin...

ENTA - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET

Reported Positive Topline Data from Phase 2 SPRINT Clinical Study of EDP-235, a 3CL Protease Inhibitor in Development as an Oral, Once-Daily Treatment for COVID-19 Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET ® /MAVIRET ® Royalties for an Up...
Previous 10 Next 10